All In Biotech

Drug Trial Radar · NCT00855855

Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease

Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines

Last checked: Nov 19, 2026Latest source record: Apr 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20,830

Actual

Start

Feb 2009

Primary completion

Dec 2014

Study completion Dec 2014

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Mar 4, 2009

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, up to 59 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To monitor the occurrence of invasive Hib disease over time and to determine product-specific rates of invasive Hib disease within the monitored population.

Conditions

  • Haemophilus Infections
  • Diphtheria
  • Tetanus
  • Polio
  • Pertussis

Interventions

  • DTaP-IPV/HibBiological

    0.5 mL, Intramuscular

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The rate of invasive Hib disease among persons within the population monitored by the Active Bacterial Core surveillance program.Time frame: Up to 6 years post vaccination

Locations

59 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Albany, California

  • Site not named

    Martinez, California

  • Site not named

    San Francisco, California

  • Site not named

    Applewood, Colorado

  • Site not named

    Aurora, Colorado

  • Site not named

    Brighton, Colorado

  • Site not named

    Castle Rock, Colorado

  • Site not named

    Denver, Colorado

  • Site not named

    Hartford, Connecticut

  • Site not named

    Adamsville, Georgia

  • Site not named

    Auburn, Georgia

  • Site not named

    Canton, Georgia

  • Site not named

    Carrollton, Georgia

  • Site not named

    Cartersville, Georgia

  • Site not named

    Conyers, Georgia

  • Site not named

    Covington, Georgia

  • Site not named

    Cumming, Georgia

  • Site not named

    Dallas, Georgia

  • Site not named

    Decatur, Georgia

  • Site not named

    Douglasville, Georgia

  • Site not named

    Fayetteville, Georgia

  • Site not named

    Good Hope, Georgia

  • Site not named

    Griffin, Georgia

  • Site not named

    Hampton, Georgia

  • Site not named

    Jasper, Georgia

  • Site not named

    Jonesboro, Georgia

  • Site not named

    Marietta, Georgia

  • Site not named

    Newnan, Georgia

  • Site not named

    Annapolis, Maryland

  • Site not named

    Saint Paul, Minnesota

  • Site not named

    Santa Fe, New Mexico

  • Site not named

    Albany, New York

  • Site not named

    Amsterdam, New York

  • Site not named

    Avon, New York

  • Site not named

    Batavia, New York

  • Site not named

    Bellona, New York

  • Site not named

    Canandaigua, New York

  • Site not named

    Catskill, New York

  • Site not named

    Chatham, New York

  • Site not named

    Geneva, New York

Showing 40 of 59 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.